PPARγ agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape

J Cell Biochem. 2023 Aug;124(8):1145-1154. doi: 10.1002/jcb.30437. Epub 2023 Jul 2.

Abstract

As a master transcription factor, c-Myc plays an important role in promoting tumor immune escape. In addition, PPARγ (peroxisome proliferator-activated receptor γ) regulates cell metabolism, inflammation, and tumor progression, while the effect of PPARγ on c-Myc-mediated tumor immune escape is still unclear. Here we found that cells treated with PPARγ agonist pioglitazone (PIOG) reduced c-Myc protein expression in a PPARγ-dependent manner. qPCR analysis showed that PIOG had no significant effect on c-Myc gene levels. Further analysis showed that PIOG decreased c-Myc protein half-life. Moreover, PIOG increased the binding of c-Myc to PPARγ, and induced c-Myc ubiquitination and degradation. Importantly, c-Myc increased PD-L1 and CD47 immune checkpoint protein expression and promoted tumor immune escape, while PIOG inhibited this event. These findings suggest that PPARγ agonist inhibited c-Myc-mediated tumor immune escape by inducing its ubiquitination and degradation.

Keywords: PPARγ agonist; c-Myc; degradation; tumor suppression; ubiquitination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Gene Expression Regulation
  • Humans
  • PPAR gamma / agonists
  • PPAR gamma / metabolism
  • Pioglitazone* / pharmacology
  • Proto-Oncogene Proteins c-myc / drug effects
  • Proto-Oncogene Proteins c-myc / metabolism
  • Thiazolidinediones* / pharmacology
  • Tumor Escape

Substances

  • Pioglitazone
  • PPAR gamma
  • Thiazolidinediones
  • Proto-Oncogene Proteins c-myc